Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1
Open Access
- 15 July 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (14), 7020-7027
- https://doi.org/10.1128/jvi.02747-05
Abstract
Resistance to zidovudine (ZDV) results from thymidine analog resistance mutations (TAMs) at human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) codons 41, 67, 70, 210, 215, and 219. Two mutations are possible at codon 215: Y or F. Whereas T215Y occurs alone or with M41L and L210W (TAM-1 pattern), T215F rarely occurs with these mutations or by itself; it is found instead with D67N, K70R, and K219Q (TAM-2 pattern). The L210W mutation most often occurs with M41L and T215Y and rarely occurs with the T215F or TAM-2 mutation. To explain these associations, TAMs were introduced into HIV-1Hxb2 by site-directed mutagenesis and expressed in recombinant viruses. Viral replication kinetics, relative fitness, and infectivity were tested in the absence or presence of ZDV. Viruses carrying the 215Y mutation showed faster replication kinetics and greater relative fitness than did T215F mutants in the absence or presence of ZDV. In addition, T215Y mutants showed greater infectivity than did wild-type HIV-1 over a range of ZDV concentrations, but T215F mutants had only a modest advantage over the wild-type virus. Whereas introduction of L210W improved the relative fitness of an M41L/T215Y mutant in the presence of ZDV, introduction of this mutation into a D67N/K70R/K219Q background resulted in decreased relative fitness in the presence or absence of drug. By contrast, introduction of T215F into the D67N/K70R/K219Q background increased viral fitness in the presence of ZDV. These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations.Keywords
This publication has 48 references indexed in Scilit:
- Clinically Relevant Genotype Interpretation of Resistance to DidanosineAntimicrobial Agents and Chemotherapy, 2005
- Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureJournal of Medical Virology, 2003
- Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical IsolatesThe Journal of Infectious Diseases, 2003
- Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215Journal of Virology, 2002
- A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV-1 Reverse Transcriptase VariantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Patterns of Resistance Mutations Selected by Treatment of Human Immunodeficiency Virus Type 1 Infection with Zidovudine, Didanosine, and NevirapineThe Journal of Infectious Diseases, 2000
- Recognition of the Highly Conserved YMDD Region in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by HLA-A2-Restricted Cytotoxic T Lymphocytes from an Asymptomatic Long-Term NonprogressorThe Journal of Infectious Diseases, 1996
- Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine TreatmentThe Journal of Infectious Diseases, 1995
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytesAIDS, 1991